ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting relating to the proposed conversion to a direct listing of ICON's shares on NASDAQ DUBLIN--(BUSINESS WIRE)

shareholders vote in favour of all resolutions at its Extraordinary

to the proposed conversion to a direct listing of ICON's shares on NASDAQ

DUBLIN--(BUSINESS WIRE)--December 18, 2012--ICON plc, (NASDAQ:ICLR)

(ISIN:IE0005711209), a global provider of outsourced development

services to the pharmaceutical, biotechnology and medical device

industries, today announced that all resolutions recommended by the

Board at the Extraordinary General Meeting ("EGM") of the Company, held

on 17th December 2012, were duly passed by shareholders.

These resolutions, relating to the proposed conversion to a direct

NASDAQ listing for ICON Shares, were set out in the Notice of the EGM

sent to shareholders on 16th November 2012 and are

available on the ICON plc website.

Forms of Proxy were received before the meeting, appointing proxies and

giving them the following voting instructions:

** Special Resolution. All resolutions are ordinary resolutions unless

Consequently, the date of delisting from the Irish Stock Exchange is

expected to be 30th January 2013 and the expected date of the

termination of the current ADR programme is 1st February

2013. The direct trading of ICON Shares on NASDAQ is expected to

commence on 4th February 2013.

The information contained in this release is as of 18th

December 2012. The statements made in this press release may contain

forward-looking statements that involve a number of risks and

uncertainties. A description of risks and uncertainties relating to ICON

and its business can be found in ICON's Annual Report for the fiscal

year ended December 31, 2011 and in the forms filed with the US

Securities and Exchange Commission, including the Forms 20-F, F-1, S-8

and F-3. ICON disclaims any intent or obligation to update these

forward-looking statements.

ICON plc is a global provider of outsourced development services to the

pharmaceutical, biotechnology and medical device industries. The company

specialises in the strategic development, management and analysis of

programs that support clinical development - from compound selection to

Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON

currently, operates from 82 locations in 40 countries and has

approximately 9,430 employees. Further information is available at www.iconplc.com.

Chief Financial Officer

VP Investor Relations